[M25-288] Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

未提供0 个研究点目标入组 900 人开始时间: 待定

适应症

试验速览

暂无简介。

•Have unresectable, metastatic histologically or cytologically confirmed adenocarcinoma of the pancreas.
•Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or
•Must consent to provide archived or recently obtained tumor tissue during Screening.
•Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

•Have prior systemic therapy, surgery, or radiation (except palliative radiation) in the unresectable, locally advanced or metastatic setting.
•Prior c-MET targeting therapy.
•History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/ pneumonitis on screening chest computed tomography (CT) scan, including a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
•Prior bone marrow transplant, solid organ transplant, or previous clinical diagnosis of tuberculosis.

发起方

未提供